CorMedix Inc
NASDAQ:CRMD

Watchlist Manager
CorMedix Inc Logo
CorMedix Inc
NASDAQ:CRMD
Watchlist
Price: 11.26 USD
Market Cap: 887.2m USD

Net Margin
CorMedix Inc

75.8%
Current
-27 603%
Average
4.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
75.8%
=
Net Income
162.5m
/
Revenue
214.3m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
CorMedix Inc
NASDAQ:CRMD
882.2m USD
76%
US
Eli Lilly and Co
NYSE:LLY
952.1B USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
494.4B USD
27%
CH
Roche Holding AG
SIX:ROG
253.5B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP
16%
CH
Novartis AG
SIX:NOVN
205.7B CHF
26%
US
Merck & Co Inc
NYSE:MRK
245.7B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
33%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
-126%
US
Pfizer Inc
NYSE:PFE
146.6B USD
16%
No Stocks Found

CorMedix Inc
Glance View

CorMedix, Inc. operates as a pharmaceutical and medical device company. The company is headquartered in Berkeley Heights, New Jersey and currently employs 29 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm's primary focus is on the development of its product candidate, DefenCath. The firm has in-licensed the rights to develop and commercialize its product candidate DefenCath. The DefenCath is a novel anti-infective solution intended for the reduction of catheter-related infections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. DefenCath product is available in Europe and other territories under the brand name Neutrolin.

CRMD Intrinsic Value
36.69 USD
Undervaluation 69%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
75.8%
=
Net Income
162.5m
/
Revenue
214.3m
What is the Net Margin of CorMedix Inc?

Based on CorMedix Inc's most recent financial statements, the company has Net Margin of 75.8%.

Back to Top